Abstract
Neuroimaging studies of cholinesterase inhibitor (ChEI) treatment in Alzheimers disease (AD) have shown the different short and long term actions of ChEIs. fMRI studies of the ChEI donepezil have focused on its short to medium term action without exploring the effects of established treatment. In this exploratory study the effect of 20 weeks donepezil treatment on regional brain activity was measured with fMRI in patients with mild AD. Twelve patients with probable AD and nine age-matched controls were assessed with a Pyramids and Palm Trees semantic association fMRI paradigm and an n-back working memory fMRI paradigm. In the patient group only, the assessment was repeated after 20 weeks of treatment. After treatment, differences from normal healthy elderly became more pronounced. There was also a spread of deactivation which at retest was detectable in task relevant areas. Behaviourally, however, there were no significant differences between group baseline and retest scores, with a range of performance probably reflecting variation in drug efficacy across patients. Parametric analyses established that increased behavioural scores at retest correlated significantly with higher activation levels in non task relevant areas. Behavioural stability with donepezil treatment was not paralleled by the pattern of improved task specific brain activation reported in similar studies of other ChEIs. This is arguably related to the different mechanisms of action of the ChEIs and might be a clinical correlate of the reported synaptic upregulation following long term donepezil treatment.
Keywords: fMRI, semantic, working memory, upregulation, pharmacodynamic
Current Alzheimer Research
Title: Established Donepezil Treatment Modulates Regional Brain Activation in Early Alzheimers Disease
Volume: 7 Issue: 5
Author(s): W.J. McGeown, M.F. Shanks, K.E. Forbes-McKay, G.D. Waiter, I. Elrick, M.G. Venneri and A. Venneri
Affiliation:
Keywords: fMRI, semantic, working memory, upregulation, pharmacodynamic
Abstract: Neuroimaging studies of cholinesterase inhibitor (ChEI) treatment in Alzheimers disease (AD) have shown the different short and long term actions of ChEIs. fMRI studies of the ChEI donepezil have focused on its short to medium term action without exploring the effects of established treatment. In this exploratory study the effect of 20 weeks donepezil treatment on regional brain activity was measured with fMRI in patients with mild AD. Twelve patients with probable AD and nine age-matched controls were assessed with a Pyramids and Palm Trees semantic association fMRI paradigm and an n-back working memory fMRI paradigm. In the patient group only, the assessment was repeated after 20 weeks of treatment. After treatment, differences from normal healthy elderly became more pronounced. There was also a spread of deactivation which at retest was detectable in task relevant areas. Behaviourally, however, there were no significant differences between group baseline and retest scores, with a range of performance probably reflecting variation in drug efficacy across patients. Parametric analyses established that increased behavioural scores at retest correlated significantly with higher activation levels in non task relevant areas. Behavioural stability with donepezil treatment was not paralleled by the pattern of improved task specific brain activation reported in similar studies of other ChEIs. This is arguably related to the different mechanisms of action of the ChEIs and might be a clinical correlate of the reported synaptic upregulation following long term donepezil treatment.
Export Options
About this article
Cite this article as:
McGeown W.J., Shanks M.F., Forbes-McKay K.E., Waiter G.D., Elrick I., Venneri M.G. and Venneri A., Established Donepezil Treatment Modulates Regional Brain Activation in Early Alzheimers Disease, Current Alzheimer Research 2010; 7 (5) . https://dx.doi.org/10.2174/156720510791383877
DOI https://dx.doi.org/10.2174/156720510791383877 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cellular Pathology in the Dorsolateral Prefrontal Cortex Distinguishes Schizophrenia from Bipolar Disorder
Current Molecular Medicine The Role of Transcranial Magnetic Stimulation in Treatment-Resistant Depression: A Review
Current Pharmaceutical Design The Discovery of VLA-4 Antagonists
Current Topics in Medicinal Chemistry Evaluation of the Radioprotective Effects of Melatonin Against Ionizing Radiation-Induced Muscle Tissue Injury
Current Radiopharmaceuticals Anti-Alzheimer Therapeutic Drugs Targeting γ-Secretase
Current Topics in Medicinal Chemistry Patent Selections
Recent Patents on DNA & Gene Sequences Psychosocial Factors and Central Sensitivity Syndromes
Current Rheumatology Reviews The Association of Microglial Activation and Amyloid Reduction in APP+PS1 Transgenic Mice
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Chiral Kinase Inhibitors
Current Topics in Medicinal Chemistry Recent Development in the Search for Effective Antidepressants Using Traditional Chinese Medicine
Central Nervous System Agents in Medicinal Chemistry Pathophysiology of Diabetic Dyslipidaemia
Current Vascular Pharmacology From Axonal Transport to Mitochondrial Trafficking: What Can We Learn from Manganese-Enhanced MRI Studies in Mouse Models of Alzheimers Disease?
Current Medical Imaging Editorial [Hot Topic: Brain Resilience and Plasticity in the Face of Alzheimer Pathology (Guest Editor: Ira Driscoll & Juan Troncoso)]
Current Alzheimer Research Non-Steroidal Anti-Inflammatory Drugs as Anti-Amyloidogenic Compounds
Current Pharmaceutical Design The Role of MAPK's Signaling in Mediating ApoE4-Driven Pathology In Vivo
Current Alzheimer Research Commentary: Participation of Sox-1 Expression and Signaling of β-Catenin in the Pathophysiology of Generalized Seizures in Cerebellum of Rat
CNS & Neurological Disorders - Drug Targets Molecular Mechanisms Regulating Matrix Metalloproteinases
Current Topics in Medicinal Chemistry The Battle of the Sexes for Stroke Therapy: Female- Versus Male-Derived Stem Cells
CNS & Neurological Disorders - Drug Targets CGRP Receptor Antagonism and Migraine Therapy
Current Protein & Peptide Science Aromatic Sulfur Compounds Enrichment from Seawater in Crude Oil Contamination by Solid Phase Extraction
Current Analytical Chemistry